21st Jun 2021 19:24
Avacta Group PLC -developer of diagnostics and cancer therapies - Enters into a non-exclusive distribution agreement with Calibre Scientific Inc, a provider of life science products, for Avacta's AffiDX SARS-CoV-2 antigen lateral flow test for professional use in the UK and European economic area. The test will be listed on Calibre's web site and available to be purchased by professional users.
Current stock price: 187.63 pence
Year-to-date change: up 65%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group